GO:0008336 gamma-butyrobetaine dioxygenase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0008336 gamma-butyrobetaine dioxygenase activity catalyzes the final step of carnitine biosynthesis: conversion of 4-(trimethylammonio)butanoate (gamma-butyrobetaine) to carnitine using 2-oxoglutarate, O2, and ascorbate.
• The enzyme is encoded by BBOX1 (gamma-butyrobetaine hydroxylase) and is highly expressed in liver, kidney, and testis; its activity is not rate-limiting for carnitine biosynthesis in human infants.
• BBOX1 expression is a prognostic biomarker in clear cell renal cell carcinoma (ccRCC), where low expression correlates with poor patient outcomes.
• BBOX1 restrains TBK1-mTORC1 oncogenic signaling in ccRCC, linking gamma-butyrobetaine dioxygenase activity to tumor suppression.
• Ascorbate (vitamin C) deficiency reduces in situ gamma-butyrobetaine hydroxylase activity, connecting the enzyme to nutritional status and carnitine homeostasis.
• CRISPR knockout, point-mutation, knock-in, and overexpression models are essential to dissect BBOX1 function in cancer, metabolism, and development.
Description
Gamma-butyrobetaine dioxygenase activity (GO:0008336) is a molecular function that catalyzes the terminal step in carnitine biosynthesis, converting gamma-butyrobetaine to carnitine in an oxygen-, 2-oxoglutarate-, and ascorbate-dependent reaction. This enzymatic activity is essential for carnitine production, which is required for fatty acid transport into mitochondria and energy metabolism. Researchers study GO:0008336 to understand metabolic regulation, nutritional requirements, and disease mechanisms, particularly in cancer and developmental biology. The enzyme is encoded by BBOX1, and its activity has been characterized across species including humans, pigs, and guinea pigs. Recent studies have identified BBOX1 as a prognostic biomarker and tumor suppressor in clear cell renal cell carcinoma, highlighting the clinical relevance of this activity.
gamma-butyrobetaine dioxygenase activity At A Glance
| GO ID | GO:0008336 |
|---|---|
| GO term | gamma-butyrobetaine dioxygenase activity |
| Ontology | molecular_function |
| Synonym | gamma-butyrobetaine hydroxylase activity; butyrobetaine hydroxylase activity; gamma-BBH activity; 4-trimethylammoniobutanoate,2-oxoglutarate:oxygen oxidoreductase (3-hydroxylating) |
| Major function | Catalyzes the final step of carnitine biosynthesis |
| Reaction | 2-oxoglutarate + 4-(trimethylammonio)butanoate + O2 = carnitine + CO2 + succinate |
| Cofactors | Ascorbate (vitamin C), Fe(II), 2-oxoglutarate |
| Gene | BBOX1 (gamma-butyrobetaine hydroxylase 1) |
| Tissue expression | Liver, kidney, testis, and other tissues |
What Is GO:0008336?
GO:0008336 gamma-butyrobetaine dioxygenase activity is defined as the catalysis of the reaction: 2-oxoglutarate + 4-(trimethylammonio)butanoate + O2 = carnitine + CO2 + succinate. In simpler terms, it is the enzyme activity that adds a hydroxyl group to gamma-butyrobetaine to produce carnitine, using 2-oxoglutarate as a co-substrate and releasing carbon dioxide and succinate.
Why Is gamma-butyrobetaine dioxygenase activity Important in Cell Biology?
Gamma-butyrobetaine dioxygenase activity is critical for carnitine biosynthesis, which is essential for mitochondrial fatty acid oxidation and energy production. Dysregulation of this activity has been linked to cancer progression, particularly in clear cell renal cell carcinoma, where BBOX1 acts as a tumor suppressor by restraining TBK1-mTORC1 signaling. Additionally, ascorbate deficiency impairs the enzyme's in situ activity, connecting nutritional status to carnitine homeostasis. Understanding GO:0008336 is therefore important for metabolic research, cancer biology, and nutritional biochemistry.
• Essential for carnitine biosynthesis and mitochondrial fatty acid oxidation.
• BBOX1 expression is a prognostic biomarker in clear cell renal cell carcinoma.
• BBOX1 restrains TBK1-mTORC1 oncogenic signaling in ccRCC.
• Ascorbate deficiency reduces gamma-butyrobetaine hydroxylase activity in vivo.
• Enzyme activity is developmentally regulated in pigs.
• BBOX1 exerts suppressive effects on HepG2 hepatoblastoma cells.
• Tissue-specific activities vary across species.
• Not rate-limiting for carnitine biosynthesis in human infants.
• Potential target for metabolic and cancer therapeutics.
• Requires Fe(II), 2-oxoglutarate, and ascorbate as cofactors.
What Happens During gamma-butyrobetaine dioxygenase activity?
Substrate binding and cofactor requirement
In simple terms: The enzyme grabs gamma-butyrobetaine and uses oxygen, vitamin C, and a helper molecule called 2-oxoglutarate to do its job.
Gamma-butyrobetaine dioxygenase binds its substrate 4-(trimethylammonio)butanoate (gamma-butyrobetaine) along with 2-oxoglutarate, molecular oxygen, and Fe(II). Ascorbate is required to maintain the iron in its active reduced state. The enzyme belongs to the 2-oxoglutarate-dependent dioxygenase family.
Catalytic hydroxylation
In simple terms: The enzyme adds an oxygen atom to gamma-butyrobetaine, turning it into carnitine.
The reaction proceeds via oxidative decarboxylation of 2-oxoglutarate, generating succinate and a highly reactive iron-oxo species that hydroxylates gamma-butyrobetaine at the C-3 position to form carnitine. Carbon dioxide is released as a byproduct.
Product release and carnitine utilization
In simple terms: The newly made carnitine is released and used by cells to transport fats into mitochondria for energy.
Carnitine produced by this activity is essential for the transport of long-chain fatty acids into mitochondria for beta-oxidation. In human infants, the activity is not rate-limiting for carnitine biosynthesis, suggesting other regulatory steps exist.
Tissue-specific and developmental regulation
In simple terms: Different tissues and developmental stages have different levels of this enzyme activity.
Gamma-butyrobetaine dioxygenase activity varies across tissues and during development. In pigs, activity is developmentally regulated and shows substrate inhibition. Tissue-specific activities have been reported in pigs and guinea pigs.
Key Genes Involved in GO:0008336 gamma-butyrobetaine dioxygenase activity
The following genes and proteins are directly involved in gamma-butyrobetaine dioxygenase activity or its regulation.
| Gene | Major Role | Research Relevance |
|---|---|---|
| BBOX1 | Encodes gamma-butyrobetaine hydroxylase, the enzyme catalyzing GO:0008336 | Prognostic biomarker in ccRCC; tumor suppressor |
| SLC22A5 | Carnitine transporter | Carnitine homeostasis |
| CPT1A | Carnitine palmitoyltransferase 1A | Fatty acid oxidation |
| CPT2 | Carnitine palmitoyltransferase 2 | Fatty acid oxidation |
| TBK1 | Kinase restrained by BBOX1 in ccRCC | Oncogenic signaling |
| MTOR | mTORC1 signaling pathway | Oncogenic signaling |
| PPARGC1A | PGC-1alpha, mitochondrial biogenesis | Metabolic regulation |
| SLC25A20 | Carnitine-acylcarnitine translocase | Fatty acid transport |
| ACADM | Medium-chain acyl-CoA dehydrogenase | Fatty acid oxidation |
| HIF1A | Hypoxia-inducible factor 1-alpha | Metabolic adaptation |
| VHL | von Hippel-Lindau tumor suppressor | ccRCC biology |
| TFE3 | Transcription factor E3 | ccRCC biology |
| TFEB | Transcription factor EB | ccRCC biology |
| GOT1 | Glutamic-oxaloacetic transaminase 1 | Metabolism |
| GOT2 | Glutamic-oxaloacetic transaminase 2 | Metabolism |
| SLC7A5 | L-type amino acid transporter 1 | Metabolism |
| SLC3A2 | 4F2 cell-surface antigen heavy chain | Metabolism |
| ASNS | Asparagine synthetase | Metabolism |
How Is gamma-butyrobetaine dioxygenase activity Regulated?
Gamma-butyrobetaine dioxygenase activity is regulated by substrate availability, cofactor levels (ascorbate, Fe(II), 2-oxoglutarate), and tissue-specific expression. Ascorbate deficiency reduces in situ enzyme activity, linking nutritional status to carnitine biosynthesis. In clear cell renal cell carcinoma, BBOX1 expression is downregulated and its loss promotes TBK1-mTORC1 oncogenic signaling. Developmental regulation of enzyme activity has been observed in pigs.
gamma-butyrobetaine dioxygenase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| BBOX1 | Clear cell renal cell carcinoma | BBOX1 knockout ccRCC cell lines (e.g., 786-O, A-498) |
| BBOX1 | Hepatoblastoma | HepG2 BBOX1 overexpression |
| BBOX1 | Carnitine deficiency | BBOX1 knockout mouse models |
| BBOX1 | Metabolic disorders | Patient-derived fibroblasts with BBOX1 mutations |
| BBOX1 | Developmental metabolism | Pig models for ontogeny studies |
Clear cell renal cell carcinoma (ccRCC)
Low BBOX1 expression is a prognostic biomarker for poor outcomes in ccRCC patients. BBOX1 restrains TBK1-mTORC1 oncogenic signaling, and its loss promotes tumor growth. These findings suggest that gamma-butyrobetaine dioxygenase activity has a tumor-suppressive role in ccRCC.
Hepatoblastoma
BBOX1 exerts suppressive effects on HepG2 hepatoblastoma cells, indicating that gamma-butyrobetaine dioxygenase activity may inhibit liver cancer cell proliferation.
Carnitine deficiency disorders
Impaired gamma-butyrobetaine dioxygenase activity can contribute to carnitine deficiency, affecting fatty acid oxidation and energy metabolism. Ascorbate deficiency further reduces enzyme activity, highlighting a nutritional link.
From gamma-butyrobetaine dioxygenase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does BBOX1 loss promote tumor growth? | BBOX1 knockout ccRCC cell lines and xenografts |
| Does BBOX1 overexpression suppress hepatoblastoma? | HepG2 BBOX1 overexpression |
| What is the role of BBOX1 in carnitine biosynthesis? | BBOX1 knockout mouse models |
| How does ascorbate deficiency affect enzyme activity? | Guinea pig liver perfusion models |
| Is BBOX1 activity developmentally regulated? | Pig tissue samples across ontogeny |
| What is the prognostic value of BBOX1 in ccRCC? | Patient tumor cohorts and machine learning |
How to Study the gamma-butyrobetaine dioxygenase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Enzymatic assay | Gamma-butyrobetaine dioxygenase activity | Tissue and cell lysates |
| RNA-seq | BBOX1 mRNA expression | Prognostic biomarker studies |
| LC-MS metabolomics | Carnitine and gamma-butyrobetaine levels | Metabolic profiling |
| Western blot | BBOX1 protein levels | Cancer cell lines |
| CRISPR knockout | Gene function loss | Cancer dependency studies |
| Overexpression | Gain-of-function | Hepatoblastoma cells |
| Machine learning | Prognostic modeling | ccRCC patient cohorts |
Enzymatic activity assays
Gamma-butyrobetaine dioxygenase activity can be measured using radiolabeled substrate or LC-MS to detect carnitine production. These assays require 2-oxoglutarate, ascorbate, and Fe(II).
Gene expression analysis
RNA-seq and qPCR are used to quantify BBOX1 mRNA levels in tissues and cell lines, as performed in ccRCC prognostic studies.
Proteomics and metabolomics
Mass spectrometry-based proteomics and metabolomics can measure BBOX1 protein levels and carnitine metabolites.
CRISPR screening
Genome-wide CRISPR knockout screens can identify synthetic lethal interactions with BBOX1 loss in cancer cells.
How CRISPR Can Be Used to Study GO:0008336 gamma-butyrobetaine dioxygenase activity
Knockout
CRISPR knockout of BBOX1 in ccRCC cell lines can test its tumor-suppressive role and its effect on TBK1-mTORC1 signaling. Knockout models also help study carnitine biosynthesis.
Point Mutation
Point mutations in BBOX1 can be introduced to dissect catalytic residues required for gamma-butyrobetaine dioxygenase activity and cofactor binding.
Knock-in
Knock-in of tagged BBOX1 (e.g., FLAG or GFP) allows localization and interaction studies in cancer cells.
Overexpression
Overexpression of BBOX1 in HepG2 cells suppresses proliferation, providing a model to study its tumor-suppressive effects.
How EDITGENE Supports gamma-butyrobetaine dioxygenase activity Research
Researchers studying gamma-butyrobetaine dioxygenase activity-related genes often need to determine whether a candidate gene is causally involved in carnitine biosynthesis, cancer progression, or metabolic regulation. EDITGENE provides comprehensive CRISPR services to accelerate this research.
Contact EDITGENE today to design your custom CRISPR model for gamma-butyrobetaine dioxygenase activity research.
Frequently Asked Questions About gamma-butyrobetaine dioxygenase activity
What is gamma-butyrobetaine dioxygenase activity?
It is the enzyme activity (GO:0008336) that catalyzes the final step of carnitine biosynthesis, converting gamma-butyrobetaine to carnitine using 2-oxoglutarate, oxygen, and ascorbate.
What gene encodes gamma-butyrobetaine dioxygenase?
The BBOX1 gene encodes gamma-butyrobetaine hydroxylase, the enzyme responsible for this activity.
What is the role of BBOX1 in cancer?
BBOX1 acts as a tumor suppressor in clear cell renal cell carcinoma by restraining TBK1-mTORC1 signaling, and low expression is a poor prognostic biomarker.
How is gamma-butyrobetaine dioxygenase activity measured?
It is measured using enzymatic assays that detect carnitine production from gamma-butyrobetaine, often with LC-MS or radiolabeled substrates.
What cofactors are required for gamma-butyrobetaine dioxygenase activity?
The enzyme requires Fe(II), 2-oxoglutarate, molecular oxygen, and ascorbate (vitamin C).
Does ascorbate deficiency affect gamma-butyrobetaine dioxygenase activity?
Yes, ascorbate deficiency reduces in situ gamma-butyrobetaine hydroxylase activity in guinea pig liver.
Is gamma-butyrobetaine dioxygenase activity rate-limiting for carnitine biosynthesis?
In human infants, it is not rate-limiting for carnitine biosynthesis.
What diseases are associated with BBOX1 dysfunction?
BBOX1 dysfunction has been linked to clear cell renal cell carcinoma, hepatoblastoma, and carnitine deficiency disorders.
How can CRISPR be used to study BBOX1?
CRISPR knockout, point mutation, knock-in, and overexpression models allow functional dissection of BBOX1 in cancer and metabolism.
What tissues express BBOX1?
BBOX1 is highly expressed in liver, kidney, and testis, with activity varying across species and developmental stages.
Conclusion
Gamma-butyrobetaine dioxygenase activity (GO:0008336) is a critical enzymatic function in carnitine biosynthesis with emerging roles in cancer suppression and metabolic regulation. BBOX1, the encoding gene, is a prognostic biomarker in ccRCC and a potential therapeutic target. Continued research using CRISPR models and multi-omics approaches will further elucidate its mechanisms and clinical applications.
References
- 1. Kim KS et al.. 2023. Low gamma-butyrobetaine dioxygenase (BBOX1) expression as a prognostic biomarker in patients with clear cell renal cell carcinoma: a machine learning approach.. J Pathol Clin Res 9(3):236-248 PMID: 36864013
- 2. Lin X et al.. 2020. Ontogeny of carnitine biosynthesis in Sus scrofa domesticus, inferred from γ-butyrobetaine hydroxylase (dioxygenase) activity and substrate inhibition.. Am J Physiol Regul Integr Comp Physiol 319(1):R43-R49 PMID: 32432915
- 3. Liao C et al.. 2025. BBOX1 restrains TBK1-mTORC1 oncogenic signaling in clear cell renal cell carcinoma.. Nat Commun 16(1):1543 PMID: 39934163
- 4. Olson AL et al.. 1987. gamma-Butyrobetaine hydroxylase activity is not rate limiting for carnitine biosynthesis in the human infant.. J Nutr 117(6):1024-31 PMID: 3110383
- 5. Dunn WA et al.. 1984. Carnitine biosynthesis from gamma-butyrobetaine and from exogenous protein-bound 6-N-trimethyl-L-lysine by the perfused guinea pig liver. Effect of ascorbate deficiency on the in situ activity of gamma-butyrobetaine hydroxylase.. J Biol Chem 259(17):10764-70 PMID: 6432788
- 6. Rebouche CJ. 1991. Ascorbic acid and carnitine biosynthesis.. Am J Clin Nutr 54(6 Suppl):1147S-1152S PMID: 1962562
- 7. Zhan Y et al.. 2024. Gamma-butyrobetaine hydroxylase (BBOX1) exerts suppressive effects on HepG2 hepatoblastoma cells.. Med Oncol 41(11):253 PMID: 39331195
- 8. Fischer M et al.. 2009. Activities of gamma-butyrobetaine dioxygenase and concentrations of carnitine in tissues of pigs.. Comp Biochem Physiol A Mol Integr Physiol 153(3):324-31 PMID: 19285565
